Dr. Li is planning for a career in non-malignant hematology, with a long-term career goal of becoming an academic hematologist and clinical researcher in the field of coagulation medicine.
The donation includes product as well as integrated care development training.
NHLB is currently seeking feedback on hemophilia inhibitors measures proposed for inclusion in the PhenX Toolkit (consensus measures for Phenotypes and eXposures).
The trials is for uniQure investigational gene therapy treatment for patients with severe and moderately severe hemophilia B.
Travel Grants to NHF's Bleeding Disorders Conference Available / Becas de viaje disponibles para la Conferencia de Trastornos Hemorrágicos de NHF
Connections for Learning and Anna DeSimone travel grant applications are now open.
Becas de viaje disponibles para la Conferencia de Trastornos Hemorrágicos de NHF.
The International Society on Thrombosis and Hemostasis (ISTH) recently developed a new tool to help clinicians identify and measure the severity of bleeding symptoms.
The case was ruled in favor of Genentech.
Researchers from the University of California (UC) Davis have been investigating whether two genetically engineered cell types could be customized for long term therapeutic benefit in individuals with hemophilia A.
Thirteen runners, nine states, thirteen miles, and one great cause: Team NHF are avid athletes who are excited to run on behalf of the bleeding disorders community.
The acquisition was approved on December 5th, 2018.